A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.

Dandamudi UB, Ghebremichael M, Sosman JA, Clark JI, McDermott DF, Atkins MB, Dutcher JP, Urba WJ, Regan MM, Puzanov I, Crocenzi TS, Curti BD, Vaishampayan UN, Crosby NA, Margolin KA, Ernstoff MS
J Immunother. 2013 36 (9): 490-5

PMID: 24145360 · DOI:10.1097/CJI.0000000000000003

MeSH Terms (23)

Adult Aged Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols Bevacizumab Carcinoma, Renal Cell Dose-Response Relationship, Drug Drug Administration Schedule Fatigue Female Follow-Up Studies Humans Hypotension Infusions, Intravenous Interleukin-2 Kaplan-Meier Estimate Karnofsky Performance Status Kidney Neoplasms Lymphopenia Male Middle Aged Neoplasm Metastasis Treatment Outcome

Connections (2)

This publication is referenced by other Labnodes entities: